[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fTZ861fkyLxJSpzNgGWxeJI18p9mVpm81LpUqj6N6uRQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":65,"rows":72},"Tufts Medical Center",[4],195,false,31,15,102015,11,120,[14,17,20,22,25,27,30,32],{"name":15,"count":16},"Heart Failure",7,{"name":18,"count":19},"Obesity",6,{"name":21,"count":19},"Psoriasis",{"name":23,"count":24},"Heart Diseases",5,{"name":26,"count":24},"Chronic Kidney Disease",{"name":28,"count":29},"Breast Cancer",4,{"name":31,"count":29},"Knee Osteoarthritis",{"name":33,"count":29},"Fibromyalgia",[35,40,45,50,55,60],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06035068","SLN Mapping and ICG Dye for Vulvar Cancer","2025-12","Indocyanine green",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05626530","Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients","2025-12-15","Letermovir",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT04682483","Cardiogenic Shock Working Group Registry","2026-01-01","Vasopressor",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06016517","Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis","2027-12-15","Etanercept",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT07473713","Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia","2028-03-01","veverimer daily",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT07448974","Vitamin D and Type 2 Diabetes - Treat-To-Target","2030-03","Vitamin D",[66,67,68,69,70,71],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[73,113,137,160,178,214,245,263,281,304,322,344,403,442,478,509,527,545,563,581,599,617,635,660,678,705,731,749,775,793,819,844,862,887,905,931,949,974,992,1017,1035,1067,1104,1131,1159,1188,1213,1241,1259,1277,1299,1317,1342,1360,1378,1396,1414,1432,1450,1468,1486,1510,1535,1567,1604,1629,1655,1673,1691,1718,1736,1761,1785,1811,1829,1855,1879,1905,1923,1941,1959,1977,1995,2024,2042,2060,2078,2101,2123,2141,2164,2189,2213,2237,2261,2284,2308,2333,2351,2376,2401,2426,2450,2475,2497,2521,2547,2573,2598,2621],{"intervention":44,"totalTrials":74,"cells":75},2,{"EARLY_PHASE1":76,"PHASE1":79,"PHASE2":81,"PHASE3":83,"PHASE4":85,"NA":111},{"trials":77,"activeCount":78},[],0,{"trials":80,"activeCount":78},[],{"trials":82,"activeCount":78},[],{"trials":84,"activeCount":78},[],{"trials":86,"activeCount":110,"soonestReadout":43},[87,102],{"nctId":88,"briefTitle":89,"status":90,"phases":91,"primaryCompletion":92,"completion":92,"start":93,"enrollment":94,"conditions":95,"interventions":101},"NCT04904614","Letermovir Use in Heart Transplant Recipients","COMPLETED",[70],"2025-01-14","2022-01-05",32,[96,97,98,99,100],"Cytomegalovirus Disease","Cytomegalovirus Infections","Heart Transplant Infection","Antiviral Toxicity","Neutropenia",[44],{"nctId":41,"briefTitle":42,"status":103,"phases":104,"primaryCompletion":43,"completion":43,"start":105,"enrollment":106,"conditions":107,"interventions":109},"RECRUITING",[70],"2023-02-02",25,[97,108,100,99],"Infection in Solid Organ Transplant Recipients",[44],1,{"trials":112,"activeCount":78},[],{"intervention":64,"totalTrials":110,"cells":114},{"EARLY_PHASE1":115,"PHASE1":117,"PHASE2":119,"PHASE3":121,"PHASE4":133,"NA":135},{"trials":116,"activeCount":78},[],{"trials":118,"activeCount":78},[],{"trials":120,"activeCount":78},[],{"trials":122,"activeCount":110,"soonestReadout":63},[123],{"nctId":61,"briefTitle":62,"status":124,"phases":125,"primaryCompletion":63,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":132},"NOT_YET_RECRUITING",[69],"2031-03","2026-05",100,[130,131],"Prediabetes","Type 2 Diabetes (T2DM)",[64],{"trials":134,"activeCount":78},[],{"trials":136,"activeCount":78},[],{"intervention":59,"totalTrials":110,"cells":138},{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":158},{"trials":140,"activeCount":78},[],{"trials":142,"activeCount":110,"soonestReadout":58},[143],{"nctId":56,"briefTitle":57,"status":103,"phases":144,"primaryCompletion":58,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":150},[67],"2028-05-01","2026-04-15",60,[149],"Osteopenia",[59,151],"veverimer every other day",{"trials":153,"activeCount":78},[],{"trials":155,"activeCount":78},[],{"trials":157,"activeCount":78},[],{"trials":159,"activeCount":78},[],{"intervention":151,"totalTrials":110,"cells":161},{"EARLY_PHASE1":162,"PHASE1":164,"PHASE2":170,"PHASE3":172,"PHASE4":174,"NA":176},{"trials":163,"activeCount":78},[],{"trials":165,"activeCount":110,"soonestReadout":58},[166],{"nctId":56,"briefTitle":57,"status":103,"phases":167,"primaryCompletion":58,"completion":145,"start":146,"enrollment":147,"conditions":168,"interventions":169},[67],[149],[59,151],{"trials":171,"activeCount":78},[],{"trials":173,"activeCount":78},[],{"trials":175,"activeCount":78},[],{"trials":177,"activeCount":78},[],{"intervention":179,"totalTrials":74,"cells":180},"Adalimumab",{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":189,"NA":202},{"trials":182,"activeCount":78},[],{"trials":184,"activeCount":78},[],{"trials":186,"activeCount":78},[],{"trials":188,"activeCount":78},[],{"trials":190,"activeCount":78},[191],{"nctId":192,"briefTitle":193,"status":90,"phases":194,"primaryCompletion":195,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":200},"NCT00932113","Mechanism of Action Study for Psoriasis",[70],"2011-12","2017-05-01","2009-06",33,[21],[201,179],"Methotrexate",{"trials":203,"activeCount":110,"soonestReadout":53},[204],{"nctId":51,"briefTitle":52,"status":124,"phases":205,"primaryCompletion":53,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":211},[],"2028-12-01","2026-05-01",18,[210],"Arthritis, Rheumatoid",[54,179,212,213],"Upadacitinib","Tocilizumab",{"intervention":213,"totalTrials":74,"cells":215},{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":222,"PHASE4":224,"NA":226},{"trials":217,"activeCount":78},[],{"trials":219,"activeCount":78},[],{"trials":221,"activeCount":78},[],{"trials":223,"activeCount":78},[],{"trials":225,"activeCount":78},[],{"trials":227,"activeCount":110,"soonestReadout":53},[228,232],{"nctId":51,"briefTitle":52,"status":124,"phases":229,"primaryCompletion":53,"completion":206,"start":207,"enrollment":208,"conditions":230,"interventions":231},[],[210],[54,179,212,213],{"nctId":233,"briefTitle":234,"status":235,"phases":236,"primaryCompletion":237,"completion":238,"start":239,"enrollment":110,"conditions":240,"interventions":243},"NCT00868751","Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis","TERMINATED",[71],"2009-11","2010-06","2009-03",[241,242],"Arthritis, Juvenile Rheumatoid","Still's Disease, Juvenile Onset",[244],"tocilizumab",{"intervention":54,"totalTrials":110,"cells":246},{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":253,"PHASE4":255,"NA":257},{"trials":248,"activeCount":78},[],{"trials":250,"activeCount":78},[],{"trials":252,"activeCount":78},[],{"trials":254,"activeCount":78},[],{"trials":256,"activeCount":78},[],{"trials":258,"activeCount":110,"soonestReadout":53},[259],{"nctId":51,"briefTitle":52,"status":124,"phases":260,"primaryCompletion":53,"completion":206,"start":207,"enrollment":208,"conditions":261,"interventions":262},[],[210],[54,179,212,213],{"intervention":212,"totalTrials":110,"cells":264},{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":273,"NA":275},{"trials":266,"activeCount":78},[],{"trials":268,"activeCount":78},[],{"trials":270,"activeCount":78},[],{"trials":272,"activeCount":78},[],{"trials":274,"activeCount":78},[],{"trials":276,"activeCount":110,"soonestReadout":53},[277],{"nctId":51,"briefTitle":52,"status":124,"phases":278,"primaryCompletion":53,"completion":206,"start":207,"enrollment":208,"conditions":279,"interventions":280},[],[210],[54,179,212,213],{"intervention":49,"totalTrials":110,"cells":282},{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":287,"PHASE3":289,"PHASE4":291,"NA":293},{"trials":284,"activeCount":78},[],{"trials":286,"activeCount":78},[],{"trials":288,"activeCount":78},[],{"trials":290,"activeCount":78},[],{"trials":292,"activeCount":78},[],{"trials":294,"activeCount":110,"soonestReadout":48},[295],{"nctId":46,"briefTitle":47,"status":103,"phases":296,"primaryCompletion":48,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":302},[],"2026-06-01","2017-12-04",5000,[301],"Cardiogenic Shock",[49,303],"Inotrope",{"intervention":303,"totalTrials":110,"cells":305},{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":310,"PHASE3":312,"PHASE4":314,"NA":316},{"trials":307,"activeCount":78},[],{"trials":309,"activeCount":78},[],{"trials":311,"activeCount":78},[],{"trials":313,"activeCount":78},[],{"trials":315,"activeCount":78},[],{"trials":317,"activeCount":110,"soonestReadout":48},[318],{"nctId":46,"briefTitle":47,"status":103,"phases":319,"primaryCompletion":48,"completion":297,"start":298,"enrollment":299,"conditions":320,"interventions":321},[],[301],[49,303],{"intervention":39,"totalTrials":110,"cells":323},{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":330,"PHASE4":332,"NA":334},{"trials":325,"activeCount":78},[],{"trials":327,"activeCount":78},[],{"trials":329,"activeCount":78},[],{"trials":331,"activeCount":78},[],{"trials":333,"activeCount":78},[],{"trials":335,"activeCount":110,"soonestReadout":38},[336],{"nctId":36,"briefTitle":37,"status":124,"phases":337,"primaryCompletion":38,"completion":338,"start":339,"enrollment":340,"conditions":341,"interventions":343},[],"2026-01","2025-11-01",10,[342],"Vulva Cancer",[39],{"intervention":345,"totalTrials":29,"cells":346},"Metformin",{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":372,"PHASE3":374,"PHASE4":389,"NA":401},{"trials":348,"activeCount":78},[],{"trials":350,"activeCount":78},[351,361],{"nctId":352,"briefTitle":353,"status":235,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":360},"NCT01440127","Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers",[67],"2012-10","2011-08",9,[359],"Colon Cancer",[345],{"nctId":362,"briefTitle":363,"status":90,"phases":364,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":371},"NCT01442870","Evaluation of Clinical Safety of Combining Metformin With Anticancer Chemotherapy",[67],"2014-02","2014-11","2011-09",105,[370],"Cancer",[345],{"trials":373,"activeCount":78},[],{"trials":375,"activeCount":78},[376],{"nctId":377,"briefTitle":378,"status":90,"phases":379,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":384,"interventions":388},"NCT05280496","A Pragmatic Approach to Lower Diabetes Risk After Gestational Diabetes",[69],"2025-03-01","2025-04-18","2022-06-01",20,[385,386,387],"Diabetes, Gestational","PreDiabetes","Diabetes Mellitus, Type 2",[345],{"trials":390,"activeCount":78},[391],{"nctId":392,"briefTitle":393,"status":90,"phases":394,"primaryCompletion":366,"completion":366,"start":395,"enrollment":383,"conditions":396,"interventions":399},"NCT01612858","Metabolic Abnormalities in HIV-infected Persons",[70],"2011-06",[397,398],"Lipodystrophy","HIV Infection",[345,400],"Pioglitazone",{"trials":402,"activeCount":78},[],{"intervention":201,"totalTrials":74,"cells":404},{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":411,"PHASE4":434,"NA":440},{"trials":406,"activeCount":78},[],{"trials":408,"activeCount":78},[],{"trials":410,"activeCount":78},[],{"trials":412,"activeCount":78},[413],{"nctId":414,"briefTitle":415,"status":235,"phases":416,"primaryCompletion":417,"completion":418,"start":237,"enrollment":419,"conditions":420,"interventions":423},"NCT01014767","Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors",[69],"2013-10","2014-01",27,[421,422],"Brain Cancer","Choroid Plexus Tumors",[424,425,426,427,428,429,430,431,201,432,433],"Carboplatin","Cisplatin","Cyclophosphamide","Dactinomycin","Doxorubicin","Etoposide","Irinotecan","Leucovorin","Temozolomide","Vincristine",{"trials":435,"activeCount":78},[436],{"nctId":192,"briefTitle":193,"status":90,"phases":437,"primaryCompletion":195,"completion":196,"start":197,"enrollment":198,"conditions":438,"interventions":439},[70],[21],[201,179],{"trials":441,"activeCount":78},[],{"intervention":443,"totalTrials":74,"cells":444},"ziprasidone",{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":449,"PHASE3":463,"PHASE4":465,"NA":476},{"trials":446,"activeCount":78},[],{"trials":448,"activeCount":78},[],{"trials":450,"activeCount":78},[451],{"nctId":452,"briefTitle":453,"status":90,"phases":454,"primaryCompletion":455,"completion":455,"start":456,"enrollment":457,"conditions":458,"interventions":462},"NCT00490542","Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State",[68],"2009-08","2006-12",73,[459,460,461],"Bipolar Disorder","Bipolar Depression","Depression",[443],{"trials":464,"activeCount":78},[],{"trials":466,"activeCount":78},[467],{"nctId":468,"briefTitle":469,"status":90,"phases":470,"primaryCompletion":195,"completion":195,"start":471,"enrollment":472,"conditions":473,"interventions":474},"NCT01168674","Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder",[70],"2010-02",49,[461,459],[443,475],"Sugar pill",{"trials":477,"activeCount":78},[],{"intervention":479,"totalTrials":110,"cells":480},"Naloxegol Oral",{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":485,"PHASE3":487,"PHASE4":489,"NA":507},{"trials":482,"activeCount":78},[],{"trials":484,"activeCount":78},[],{"trials":486,"activeCount":78},[],{"trials":488,"activeCount":78},[],{"trials":490,"activeCount":78},[491],{"nctId":492,"briefTitle":493,"status":235,"phases":494,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":498,"interventions":500},"NCT02977286","Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids",[70],"2019-10-09","2017-01-01",12,[499],"Constipation",[479,501,502,503,504,505,506],"Docusate Sodium 100 Mg oral capsule [Colace]","Senna 217 Mg Oral","Polyethylene Glycols","Bisacodyl 10 mg Suppository","Magnesium Citrate Oral Liquid Product","Methylnaltrexone",{"trials":508,"activeCount":78},[],{"intervention":501,"totalTrials":110,"cells":510},{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":517,"PHASE4":519,"NA":525},{"trials":512,"activeCount":78},[],{"trials":514,"activeCount":78},[],{"trials":516,"activeCount":78},[],{"trials":518,"activeCount":78},[],{"trials":520,"activeCount":78},[521],{"nctId":492,"briefTitle":493,"status":235,"phases":522,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":523,"interventions":524},[70],[499],[479,501,502,503,504,505,506],{"trials":526,"activeCount":78},[],{"intervention":502,"totalTrials":110,"cells":528},{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":533,"PHASE3":535,"PHASE4":537,"NA":543},{"trials":530,"activeCount":78},[],{"trials":532,"activeCount":78},[],{"trials":534,"activeCount":78},[],{"trials":536,"activeCount":78},[],{"trials":538,"activeCount":78},[539],{"nctId":492,"briefTitle":493,"status":235,"phases":540,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":541,"interventions":542},[70],[499],[479,501,502,503,504,505,506],{"trials":544,"activeCount":78},[],{"intervention":503,"totalTrials":110,"cells":546},{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":551,"PHASE3":553,"PHASE4":555,"NA":561},{"trials":548,"activeCount":78},[],{"trials":550,"activeCount":78},[],{"trials":552,"activeCount":78},[],{"trials":554,"activeCount":78},[],{"trials":556,"activeCount":78},[557],{"nctId":492,"briefTitle":493,"status":235,"phases":558,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":559,"interventions":560},[70],[499],[479,501,502,503,504,505,506],{"trials":562,"activeCount":78},[],{"intervention":504,"totalTrials":110,"cells":564},{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":569,"PHASE3":571,"PHASE4":573,"NA":579},{"trials":566,"activeCount":78},[],{"trials":568,"activeCount":78},[],{"trials":570,"activeCount":78},[],{"trials":572,"activeCount":78},[],{"trials":574,"activeCount":78},[575],{"nctId":492,"briefTitle":493,"status":235,"phases":576,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":577,"interventions":578},[70],[499],[479,501,502,503,504,505,506],{"trials":580,"activeCount":78},[],{"intervention":505,"totalTrials":110,"cells":582},{"EARLY_PHASE1":583,"PHASE1":585,"PHASE2":587,"PHASE3":589,"PHASE4":591,"NA":597},{"trials":584,"activeCount":78},[],{"trials":586,"activeCount":78},[],{"trials":588,"activeCount":78},[],{"trials":590,"activeCount":78},[],{"trials":592,"activeCount":78},[593],{"nctId":492,"briefTitle":493,"status":235,"phases":594,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":595,"interventions":596},[70],[499],[479,501,502,503,504,505,506],{"trials":598,"activeCount":78},[],{"intervention":506,"totalTrials":110,"cells":600},{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":609,"NA":615},{"trials":602,"activeCount":78},[],{"trials":604,"activeCount":78},[],{"trials":606,"activeCount":78},[],{"trials":608,"activeCount":78},[],{"trials":610,"activeCount":78},[611],{"nctId":492,"briefTitle":493,"status":235,"phases":612,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":613,"interventions":614},[70],[499],[479,501,502,503,504,505,506],{"trials":616,"activeCount":78},[],{"intervention":475,"totalTrials":110,"cells":618},{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":625,"PHASE4":627,"NA":633},{"trials":620,"activeCount":78},[],{"trials":622,"activeCount":78},[],{"trials":624,"activeCount":78},[],{"trials":626,"activeCount":78},[],{"trials":628,"activeCount":78},[629],{"nctId":468,"briefTitle":469,"status":90,"phases":630,"primaryCompletion":195,"completion":195,"start":471,"enrollment":472,"conditions":631,"interventions":632},[70],[461,459],[443,475],{"trials":634,"activeCount":78},[],{"intervention":636,"totalTrials":110,"cells":637},"Chloroprocaine",{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":644,"PHASE4":646,"NA":658},{"trials":639,"activeCount":78},[],{"trials":641,"activeCount":78},[],{"trials":643,"activeCount":78},[],{"trials":645,"activeCount":78},[],{"trials":647,"activeCount":78},[648],{"nctId":649,"briefTitle":650,"status":90,"phases":651,"primaryCompletion":652,"completion":652,"start":653,"enrollment":340,"conditions":654,"interventions":656},"NCT03305575","Intrathecal Chloroprocaine vs. Bupivacaine for Cervical Cerclage",[70],"2018-08-24","2017-10-13",[655],"Cervical Incompetence",[636,657],"Bupivacaine",{"trials":659,"activeCount":78},[],{"intervention":657,"totalTrials":110,"cells":661},{"EARLY_PHASE1":662,"PHASE1":664,"PHASE2":666,"PHASE3":668,"PHASE4":670,"NA":676},{"trials":663,"activeCount":78},[],{"trials":665,"activeCount":78},[],{"trials":667,"activeCount":78},[],{"trials":669,"activeCount":78},[],{"trials":671,"activeCount":78},[672],{"nctId":649,"briefTitle":650,"status":90,"phases":673,"primaryCompletion":652,"completion":652,"start":653,"enrollment":340,"conditions":674,"interventions":675},[70],[655],[636,657],{"trials":677,"activeCount":78},[],{"intervention":679,"totalTrials":110,"cells":680},"Spironolactone",{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":687,"PHASE4":689,"NA":703},{"trials":682,"activeCount":78},[],{"trials":684,"activeCount":78},[],{"trials":686,"activeCount":78},[],{"trials":688,"activeCount":78},[],{"trials":690,"activeCount":78},[691],{"nctId":692,"briefTitle":693,"status":90,"phases":694,"primaryCompletion":695,"completion":696,"start":697,"enrollment":698,"conditions":699,"interventions":702},"NCT00879060","Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy",[70],"2011-11","2012-11","2007-11",53,[700,701],"Myocardial Fibrosis","Hypertrophic Cardiomyopathy",[679],{"trials":704,"activeCount":78},[],{"intervention":706,"totalTrials":110,"cells":707},"Prasugrel",{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":712,"PHASE3":714,"PHASE4":716,"NA":729},{"trials":709,"activeCount":78},[],{"trials":711,"activeCount":78},[],{"trials":713,"activeCount":78},[],{"trials":715,"activeCount":78},[],{"trials":717,"activeCount":78},[718],{"nctId":719,"briefTitle":720,"status":90,"phases":721,"primaryCompletion":722,"completion":722,"start":723,"enrollment":724,"conditions":725,"interventions":727},"NCT01789814","Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation",[70],"2014-07","2013-07",24,[726],"Coronary Artery Disease",[706,728],"Clopidogrel",{"trials":730,"activeCount":78},[],{"intervention":728,"totalTrials":110,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":739,"PHASE4":741,"NA":747},{"trials":734,"activeCount":78},[],{"trials":736,"activeCount":78},[],{"trials":738,"activeCount":78},[],{"trials":740,"activeCount":78},[],{"trials":742,"activeCount":78},[743],{"nctId":719,"briefTitle":720,"status":90,"phases":744,"primaryCompletion":722,"completion":722,"start":723,"enrollment":724,"conditions":745,"interventions":746},[70],[726],[706,728],{"trials":748,"activeCount":78},[],{"intervention":750,"totalTrials":110,"cells":751},"Lotemax",{"EARLY_PHASE1":752,"PHASE1":754,"PHASE2":756,"PHASE3":758,"PHASE4":760,"NA":773},{"trials":753,"activeCount":78},[],{"trials":755,"activeCount":78},[],{"trials":757,"activeCount":78},[],{"trials":759,"activeCount":78},[],{"trials":761,"activeCount":78},[762],{"nctId":763,"briefTitle":764,"status":90,"phases":765,"primaryCompletion":766,"completion":767,"start":365,"enrollment":768,"conditions":769,"interventions":771},"NCT02120079","The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED",[70],"2017-04","2018-01-28",37,[770],"Dry Eye Disease",[750,772],"Soothe Tired Eyes Lubricant Eye Drop",{"trials":774,"activeCount":78},[],{"intervention":772,"totalTrials":110,"cells":776},{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":781,"PHASE3":783,"PHASE4":785,"NA":791},{"trials":778,"activeCount":78},[],{"trials":780,"activeCount":78},[],{"trials":782,"activeCount":78},[],{"trials":784,"activeCount":78},[],{"trials":786,"activeCount":78},[787],{"nctId":763,"briefTitle":764,"status":90,"phases":788,"primaryCompletion":766,"completion":767,"start":365,"enrollment":768,"conditions":789,"interventions":790},[70],[770],[750,772],{"trials":792,"activeCount":78},[],{"intervention":794,"totalTrials":110,"cells":795},"Dextenza",{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":802,"PHASE4":804,"NA":817},{"trials":797,"activeCount":78},[],{"trials":799,"activeCount":78},[],{"trials":801,"activeCount":78},[],{"trials":803,"activeCount":78},[],{"trials":805,"activeCount":78},[806],{"nctId":807,"briefTitle":808,"status":235,"phases":809,"primaryCompletion":810,"completion":811,"start":812,"enrollment":813,"conditions":814,"interventions":816},"NCT04527887","Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)",[70],"2023-11-17","2024-12-31","2020-09-04",54,[815],"Dry Eye",[794],{"trials":818,"activeCount":78},[],{"intervention":820,"totalTrials":110,"cells":821},"Preservative-free Refresh Optive Advanced Lubricant Eye Drops",{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":828,"PHASE4":830,"NA":842},{"trials":823,"activeCount":78},[],{"trials":825,"activeCount":78},[],{"trials":827,"activeCount":78},[],{"trials":829,"activeCount":78},[],{"trials":831,"activeCount":78},[832],{"nctId":833,"briefTitle":834,"status":235,"phases":835,"primaryCompletion":836,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":841},"NCT04125134","Predicting the Success of Dry Eye Disease Interventions Using Clinical Tests",[70],"2024-10-11","2025-07-31","2019-10-03",36,[815],[820],{"trials":843,"activeCount":78},[],{"intervention":400,"totalTrials":110,"cells":845},{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":852,"PHASE4":854,"NA":860},{"trials":847,"activeCount":78},[],{"trials":849,"activeCount":78},[],{"trials":851,"activeCount":78},[],{"trials":853,"activeCount":78},[],{"trials":855,"activeCount":78},[856],{"nctId":392,"briefTitle":393,"status":90,"phases":857,"primaryCompletion":366,"completion":366,"start":395,"enrollment":383,"conditions":858,"interventions":859},[70],[397,398],[345,400],{"trials":861,"activeCount":78},[],{"intervention":863,"totalTrials":110,"cells":864},"Chlorhexidine gluconate",{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":871,"PHASE4":873,"NA":885},{"trials":866,"activeCount":78},[],{"trials":868,"activeCount":78},[],{"trials":870,"activeCount":78},[],{"trials":872,"activeCount":78},[],{"trials":874,"activeCount":78},[875],{"nctId":876,"briefTitle":877,"status":90,"phases":878,"primaryCompletion":879,"completion":879,"start":367,"enrollment":880,"conditions":881,"interventions":883},"NCT01537783","Evaluation of a Staphylococcus Eradication Protocol for Patients Who Present to the ED With Cutaneous Abscess",[70],"2013-09",50,[882],"Cutaneous Abscess",[863,884],"Mupirocin",{"trials":886,"activeCount":78},[],{"intervention":884,"totalTrials":110,"cells":888},{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":895,"PHASE4":897,"NA":903},{"trials":890,"activeCount":78},[],{"trials":892,"activeCount":78},[],{"trials":894,"activeCount":78},[],{"trials":896,"activeCount":78},[],{"trials":898,"activeCount":78},[899],{"nctId":876,"briefTitle":877,"status":90,"phases":900,"primaryCompletion":879,"completion":879,"start":367,"enrollment":880,"conditions":901,"interventions":902},[70],[882],[863,884],{"trials":904,"activeCount":78},[],{"intervention":906,"totalTrials":110,"cells":907},"Triamcinolone Acetonide",{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":914,"PHASE4":916,"NA":929},{"trials":909,"activeCount":78},[],{"trials":911,"activeCount":78},[],{"trials":913,"activeCount":78},[],{"trials":915,"activeCount":78},[],{"trials":917,"activeCount":78},[918],{"nctId":919,"briefTitle":920,"status":90,"phases":921,"primaryCompletion":922,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":927},"NCT01230424","Effect of Steroid Injections in a Knee With Osteoarthritis",[70],"2015-01","2011-03",140,[926],"Osteoarthritis (OA) of the Knee",[906,928],"0.9% Sodium Chloride Injection as Placebo",{"trials":930,"activeCount":78},[],{"intervention":928,"totalTrials":110,"cells":932},{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":937,"PHASE3":939,"PHASE4":941,"NA":947},{"trials":934,"activeCount":78},[],{"trials":936,"activeCount":78},[],{"trials":938,"activeCount":78},[],{"trials":940,"activeCount":78},[],{"trials":942,"activeCount":78},[943],{"nctId":919,"briefTitle":920,"status":90,"phases":944,"primaryCompletion":922,"completion":922,"start":923,"enrollment":924,"conditions":945,"interventions":946},[70],[926],[906,928],{"trials":948,"activeCount":78},[],{"intervention":950,"totalTrials":110,"cells":951},"Niacin",{"EARLY_PHASE1":952,"PHASE1":954,"PHASE2":956,"PHASE3":958,"PHASE4":960,"NA":972},{"trials":953,"activeCount":78},[],{"trials":955,"activeCount":78},[],{"trials":957,"activeCount":78},[],{"trials":959,"activeCount":78},[],{"trials":961,"activeCount":78},[962],{"nctId":963,"briefTitle":964,"status":90,"phases":965,"primaryCompletion":966,"completion":966,"start":967,"enrollment":968,"conditions":969,"interventions":970},"NCT00852969","Niacin and Endothelial Function in Early CKD",[70],"2012-04","2008-08",30,[26],[950,971],"Active Placebo",{"trials":973,"activeCount":78},[],{"intervention":971,"totalTrials":110,"cells":975},{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":982,"PHASE4":984,"NA":990},{"trials":977,"activeCount":78},[],{"trials":979,"activeCount":78},[],{"trials":981,"activeCount":78},[],{"trials":983,"activeCount":78},[],{"trials":985,"activeCount":78},[986],{"nctId":963,"briefTitle":964,"status":90,"phases":987,"primaryCompletion":966,"completion":966,"start":967,"enrollment":968,"conditions":988,"interventions":989},[70],[26],[950,971],{"trials":991,"activeCount":78},[],{"intervention":993,"totalTrials":110,"cells":994},"Amitriptyline",{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":999,"PHASE3":1001,"PHASE4":1003,"NA":1015},{"trials":996,"activeCount":78},[],{"trials":998,"activeCount":78},[],{"trials":1000,"activeCount":78},[],{"trials":1002,"activeCount":78},[],{"trials":1004,"activeCount":78},[1005],{"nctId":1006,"briefTitle":1007,"status":90,"phases":1008,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":1011,"conditions":1012,"interventions":1013},"NCT00000428","Combining N-of-1 Trials to Assess Fibromyalgia Treatments",[70],"2004-03","2000-09",58,[33],[993,1014],"Amitriptyline plus Fluoxitine",{"trials":1016,"activeCount":78},[],{"intervention":1014,"totalTrials":110,"cells":1018},{"EARLY_PHASE1":1019,"PHASE1":1021,"PHASE2":1023,"PHASE3":1025,"PHASE4":1027,"NA":1033},{"trials":1020,"activeCount":78},[],{"trials":1022,"activeCount":78},[],{"trials":1024,"activeCount":78},[],{"trials":1026,"activeCount":78},[],{"trials":1028,"activeCount":78},[1029],{"nctId":1006,"briefTitle":1007,"status":90,"phases":1030,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":1011,"conditions":1031,"interventions":1032},[70],[33],[993,1014],{"trials":1034,"activeCount":78},[],{"intervention":424,"totalTrials":74,"cells":1036},{"EARLY_PHASE1":1037,"PHASE1":1039,"PHASE2":1041,"PHASE3":1057,"PHASE4":1063,"NA":1065},{"trials":1038,"activeCount":78},[],{"trials":1040,"activeCount":78},[],{"trials":1042,"activeCount":78},[1043],{"nctId":1044,"briefTitle":1045,"status":235,"phases":1046,"primaryCompletion":1047,"completion":1047,"start":1048,"enrollment":24,"conditions":1049,"interventions":1052},"NCT04856176","A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy",[68],"2024-12-06","2022-01-03",[1050,1051],"Advanced Lung Non-Small Cell Carcinoma","Non-Small Cell Carcinoma of Lung, TNM Stage 4",[1053,1054,1055,1056,424],"Granulocyte-Macrophage Colony-Stimulating Factor","Pembrolizumab","pemetrexed","Paclitaxel",{"trials":1058,"activeCount":78},[1059],{"nctId":414,"briefTitle":415,"status":235,"phases":1060,"primaryCompletion":417,"completion":418,"start":237,"enrollment":419,"conditions":1061,"interventions":1062},[69],[421,422],[424,425,426,427,428,429,430,431,201,432,433],{"trials":1064,"activeCount":78},[],{"trials":1066,"activeCount":78},[],{"intervention":1068,"totalTrials":74,"cells":1069},"Liposomal bupivacaine",{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1074,"PHASE3":1086,"PHASE4":1100,"NA":1102},{"trials":1071,"activeCount":78},[],{"trials":1073,"activeCount":78},[],{"trials":1075,"activeCount":78},[1076],{"nctId":1077,"briefTitle":1078,"status":90,"phases":1079,"primaryCompletion":1080,"completion":1080,"start":1081,"enrollment":1082,"conditions":1083,"interventions":1084},"NCT04603911","RCT Comparing ESPB Solutions in Breast Surgery",[68],"2023-04-10","2020-12-04",75,[28],[1068,1085],"Bupivacaine, epinephrine, dexamethasone, and clonidine",{"trials":1087,"activeCount":78},[1088],{"nctId":1089,"briefTitle":1090,"status":90,"phases":1091,"primaryCompletion":1092,"completion":1093,"start":1094,"enrollment":9,"conditions":1095,"interventions":1098},"NCT05763667","Pilot: Intraoperative TAP Block and Post-operative Pain Control for Minimally Invasive Hysterectomy for Endometrial Cancer",[69],"2024-07-01","2024-09-09","2024-01-01",[1096,1097],"Post Operative Pain","Gynecologic Cancer",[1068,1099],"Bupivacain",{"trials":1101,"activeCount":78},[],{"trials":1103,"activeCount":78},[],{"intervention":432,"totalTrials":74,"cells":1105},{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1119,"PHASE3":1121,"PHASE4":1127,"NA":1129},{"trials":1107,"activeCount":78},[],{"trials":1109,"activeCount":78},[1110],{"nctId":1111,"briefTitle":1112,"status":235,"phases":1113,"primaryCompletion":966,"completion":966,"start":1114,"enrollment":74,"conditions":1115,"interventions":1118},"NCT00629187","Safety Study of High Dose Temozolomide to Treat Relapsed\u002FRefractory Central Nervous System (CNS) Malignancy",[67],"2004-04",[1116,1117],"Central Nervous System Neoplasms","Neoplasm Metastasis",[432],{"trials":1120,"activeCount":78},[],{"trials":1122,"activeCount":78},[1123],{"nctId":414,"briefTitle":415,"status":235,"phases":1124,"primaryCompletion":417,"completion":418,"start":237,"enrollment":419,"conditions":1125,"interventions":1126},[69],[421,422],[424,425,426,427,428,429,430,431,201,432,433],{"trials":1128,"activeCount":78},[],{"trials":1130,"activeCount":78},[],{"intervention":1132,"totalTrials":110,"cells":1133},"Ketorolac",{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1138,"PHASE3":1140,"PHASE4":1155,"NA":1157},{"trials":1135,"activeCount":78},[],{"trials":1137,"activeCount":78},[],{"trials":1139,"activeCount":78},[],{"trials":1141,"activeCount":78},[1142],{"nctId":1143,"briefTitle":1144,"status":90,"phases":1145,"primaryCompletion":1146,"completion":1147,"start":1148,"enrollment":1149,"conditions":1150,"interventions":1154},"NCT03678675","Increased Ketorolac Administration After Cesarean Section and Its Effect on Opioid Use: a Randomized Control Trial",[69],"2022-01-31","2022-06-30","2019-05-30",148,[1151,1152,1153],"Post-operative Pain","Post-partum Pain","Cesarean Section Complications",[1132],{"trials":1156,"activeCount":78},[],{"trials":1158,"activeCount":78},[],{"intervention":1160,"totalTrials":110,"cells":1161},"GIK",{"EARLY_PHASE1":1162,"PHASE1":1164,"PHASE2":1166,"PHASE3":1168,"PHASE4":1184,"NA":1186},{"trials":1163,"activeCount":78},[],{"trials":1165,"activeCount":78},[],{"trials":1167,"activeCount":78},[],{"trials":1169,"activeCount":78},[1170],{"nctId":1171,"briefTitle":1172,"status":90,"phases":1173,"primaryCompletion":356,"completion":1174,"start":1175,"enrollment":1176,"conditions":1177,"interventions":1183},"NCT00091507","IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.",[69],"2012-08","2006-11",911,[1178,1179,23,1180,1181,1182],"Angina, Unstable","Cardiovascular Diseases","Coronary Disease","Myocardial Infarction","Heart Failure, Congestive",[1160],{"trials":1185,"activeCount":78},[],{"trials":1187,"activeCount":78},[],{"intervention":1189,"totalTrials":110,"cells":1190},"Acetaminophen",{"EARLY_PHASE1":1191,"PHASE1":1193,"PHASE2":1195,"PHASE3":1197,"PHASE4":1209,"NA":1211},{"trials":1192,"activeCount":78},[],{"trials":1194,"activeCount":78},[],{"trials":1196,"activeCount":78},[],{"trials":1198,"activeCount":78},[1199],{"nctId":1200,"briefTitle":1201,"status":90,"phases":1202,"primaryCompletion":1203,"completion":1203,"start":1204,"enrollment":1205,"conditions":1206,"interventions":1208},"NCT03131713","Preoperative Acetaminophen and Carbohydrate Loading",[69],"2017-12-31","2016-07-01",101,[1207],"Non-melanoma Skin Cancer",[1189],{"trials":1210,"activeCount":78},[],{"trials":1212,"activeCount":78},[],{"intervention":1214,"totalTrials":110,"cells":1215},"Neonatal Morphine Solution",{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1220,"PHASE3":1222,"PHASE4":1237,"NA":1239},{"trials":1217,"activeCount":78},[],{"trials":1219,"activeCount":78},[],{"trials":1221,"activeCount":78},[],{"trials":1223,"activeCount":78},[1224],{"nctId":1225,"briefTitle":1226,"status":90,"phases":1227,"primaryCompletion":1228,"completion":1229,"start":879,"enrollment":1230,"conditions":1231,"interventions":1234},"NCT01958476","Improving Outcomes in Neonatal Abstinence Syndrome",[69],"2017-03-05","2018-08-30",117,[1232,1233],"Neonatal Abstinence Syndrome","Neonatal Opioid Withdrawal",[1214,1235,1236],"Methadone","Phenobarbital",{"trials":1238,"activeCount":78},[],{"trials":1240,"activeCount":78},[],{"intervention":1235,"totalTrials":110,"cells":1242},{"EARLY_PHASE1":1243,"PHASE1":1245,"PHASE2":1247,"PHASE3":1249,"PHASE4":1255,"NA":1257},{"trials":1244,"activeCount":78},[],{"trials":1246,"activeCount":78},[],{"trials":1248,"activeCount":78},[],{"trials":1250,"activeCount":78},[1251],{"nctId":1225,"briefTitle":1226,"status":90,"phases":1252,"primaryCompletion":1228,"completion":1229,"start":879,"enrollment":1230,"conditions":1253,"interventions":1254},[69],[1232,1233],[1214,1235,1236],{"trials":1256,"activeCount":78},[],{"trials":1258,"activeCount":78},[],{"intervention":1236,"totalTrials":110,"cells":1260},{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1265,"PHASE3":1267,"PHASE4":1273,"NA":1275},{"trials":1262,"activeCount":78},[],{"trials":1264,"activeCount":78},[],{"trials":1266,"activeCount":78},[],{"trials":1268,"activeCount":78},[1269],{"nctId":1225,"briefTitle":1226,"status":90,"phases":1270,"primaryCompletion":1228,"completion":1229,"start":879,"enrollment":1230,"conditions":1271,"interventions":1272},[69],[1232,1233],[1214,1235,1236],{"trials":1274,"activeCount":78},[],{"trials":1276,"activeCount":78},[],{"intervention":1278,"totalTrials":110,"cells":1279},"citalopram + mood stabilizer",{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1284,"PHASE3":1286,"PHASE4":1295,"NA":1297},{"trials":1281,"activeCount":78},[],{"trials":1283,"activeCount":78},[],{"trials":1285,"activeCount":78},[],{"trials":1287,"activeCount":78},[1288],{"nctId":1289,"briefTitle":1290,"status":90,"phases":1291,"primaryCompletion":722,"completion":722,"start":697,"enrollment":1292,"conditions":1293,"interventions":1294},"NCT00562861","Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram",[68,69],119,[459,460],[1278],{"trials":1296,"activeCount":78},[],{"trials":1298,"activeCount":78},[],{"intervention":1099,"totalTrials":110,"cells":1300},{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1307,"PHASE4":1313,"NA":1315},{"trials":1302,"activeCount":78},[],{"trials":1304,"activeCount":78},[],{"trials":1306,"activeCount":78},[],{"trials":1308,"activeCount":78},[1309],{"nctId":1089,"briefTitle":1090,"status":90,"phases":1310,"primaryCompletion":1092,"completion":1093,"start":1094,"enrollment":9,"conditions":1311,"interventions":1312},[69],[1096,1097],[1068,1099],{"trials":1314,"activeCount":78},[],{"trials":1316,"activeCount":78},[],{"intervention":1318,"totalTrials":110,"cells":1319},"Cholecalciferol",{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1324,"PHASE3":1326,"PHASE4":1338,"NA":1340},{"trials":1321,"activeCount":78},[],{"trials":1323,"activeCount":78},[],{"trials":1325,"activeCount":78},[],{"trials":1327,"activeCount":78},[1328],{"nctId":1329,"briefTitle":1330,"status":90,"phases":1331,"primaryCompletion":1332,"completion":1332,"start":1333,"enrollment":1334,"conditions":1335,"interventions":1337},"NCT01736865","Vitamin D for Established Type 2 Diabetes (DDM2)",[68,69],"2015-08","2012-12",127,[1336],"Type 2 Diabetes",[1318],{"trials":1339,"activeCount":78},[],{"trials":1341,"activeCount":78},[],{"intervention":425,"totalTrials":110,"cells":1343},{"EARLY_PHASE1":1344,"PHASE1":1346,"PHASE2":1348,"PHASE3":1350,"PHASE4":1356,"NA":1358},{"trials":1345,"activeCount":78},[],{"trials":1347,"activeCount":78},[],{"trials":1349,"activeCount":78},[],{"trials":1351,"activeCount":78},[1352],{"nctId":414,"briefTitle":415,"status":235,"phases":1353,"primaryCompletion":417,"completion":418,"start":237,"enrollment":419,"conditions":1354,"interventions":1355},[69],[421,422],[424,425,426,427,428,429,430,431,201,432,433],{"trials":1357,"activeCount":78},[],{"trials":1359,"activeCount":78},[],{"intervention":426,"totalTrials":110,"cells":1361},{"EARLY_PHASE1":1362,"PHASE1":1364,"PHASE2":1366,"PHASE3":1368,"PHASE4":1374,"NA":1376},{"trials":1363,"activeCount":78},[],{"trials":1365,"activeCount":78},[],{"trials":1367,"activeCount":78},[],{"trials":1369,"activeCount":78},[1370],{"nctId":414,"briefTitle":415,"status":235,"phases":1371,"primaryCompletion":417,"completion":418,"start":237,"enrollment":419,"conditions":1372,"interventions":1373},[69],[421,422],[424,425,426,427,428,429,430,431,201,432,433],{"trials":1375,"activeCount":78},[],{"trials":1377,"activeCount":78},[],{"intervention":427,"totalTrials":110,"cells":1379},{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1386,"PHASE4":1392,"NA":1394},{"trials":1381,"activeCount":78},[],{"trials":1383,"activeCount":78},[],{"trials":1385,"activeCount":78},[],{"trials":1387,"activeCount":78},[1388],{"nctId":414,"briefTitle":415,"status":235,"phases":1389,"primaryCompletion":417,"completion":418,"start":237,"enrollment":419,"conditions":1390,"interventions":1391},[69],[421,422],[424,425,426,427,428,429,430,431,201,432,433],{"trials":1393,"activeCount":78},[],{"trials":1395,"activeCount":78},[],{"intervention":428,"totalTrials":110,"cells":1397},{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1402,"PHASE3":1404,"PHASE4":1410,"NA":1412},{"trials":1399,"activeCount":78},[],{"trials":1401,"activeCount":78},[],{"trials":1403,"activeCount":78},[],{"trials":1405,"activeCount":78},[1406],{"nctId":414,"briefTitle":415,"status":235,"phases":1407,"primaryCompletion":417,"completion":418,"start":237,"enrollment":419,"conditions":1408,"interventions":1409},[69],[421,422],[424,425,426,427,428,429,430,431,201,432,433],{"trials":1411,"activeCount":78},[],{"trials":1413,"activeCount":78},[],{"intervention":429,"totalTrials":110,"cells":1415},{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1420,"PHASE3":1422,"PHASE4":1428,"NA":1430},{"trials":1417,"activeCount":78},[],{"trials":1419,"activeCount":78},[],{"trials":1421,"activeCount":78},[],{"trials":1423,"activeCount":78},[1424],{"nctId":414,"briefTitle":415,"status":235,"phases":1425,"primaryCompletion":417,"completion":418,"start":237,"enrollment":419,"conditions":1426,"interventions":1427},[69],[421,422],[424,425,426,427,428,429,430,431,201,432,433],{"trials":1429,"activeCount":78},[],{"trials":1431,"activeCount":78},[],{"intervention":430,"totalTrials":110,"cells":1433},{"EARLY_PHASE1":1434,"PHASE1":1436,"PHASE2":1438,"PHASE3":1440,"PHASE4":1446,"NA":1448},{"trials":1435,"activeCount":78},[],{"trials":1437,"activeCount":78},[],{"trials":1439,"activeCount":78},[],{"trials":1441,"activeCount":78},[1442],{"nctId":414,"briefTitle":415,"status":235,"phases":1443,"primaryCompletion":417,"completion":418,"start":237,"enrollment":419,"conditions":1444,"interventions":1445},[69],[421,422],[424,425,426,427,428,429,430,431,201,432,433],{"trials":1447,"activeCount":78},[],{"trials":1449,"activeCount":78},[],{"intervention":431,"totalTrials":110,"cells":1451},{"EARLY_PHASE1":1452,"PHASE1":1454,"PHASE2":1456,"PHASE3":1458,"PHASE4":1464,"NA":1466},{"trials":1453,"activeCount":78},[],{"trials":1455,"activeCount":78},[],{"trials":1457,"activeCount":78},[],{"trials":1459,"activeCount":78},[1460],{"nctId":414,"briefTitle":415,"status":235,"phases":1461,"primaryCompletion":417,"completion":418,"start":237,"enrollment":419,"conditions":1462,"interventions":1463},[69],[421,422],[424,425,426,427,428,429,430,431,201,432,433],{"trials":1465,"activeCount":78},[],{"trials":1467,"activeCount":78},[],{"intervention":433,"totalTrials":110,"cells":1469},{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1474,"PHASE3":1476,"PHASE4":1482,"NA":1484},{"trials":1471,"activeCount":78},[],{"trials":1473,"activeCount":78},[],{"trials":1475,"activeCount":78},[],{"trials":1477,"activeCount":78},[1478],{"nctId":414,"briefTitle":415,"status":235,"phases":1479,"primaryCompletion":417,"completion":418,"start":237,"enrollment":419,"conditions":1480,"interventions":1481},[69],[421,422],[424,425,426,427,428,429,430,431,201,432,433],{"trials":1483,"activeCount":78},[],{"trials":1485,"activeCount":78},[],{"intervention":1487,"totalTrials":110,"cells":1488},"inhaled nitric oxide",{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1493,"PHASE3":1495,"PHASE4":1506,"NA":1508},{"trials":1490,"activeCount":78},[],{"trials":1492,"activeCount":78},[],{"trials":1494,"activeCount":78},[],{"trials":1496,"activeCount":78},[1497],{"nctId":1498,"briefTitle":1499,"status":235,"phases":1500,"primaryCompletion":722,"completion":722,"start":1501,"enrollment":1502,"conditions":1503,"interventions":1505},"NCT01748045","Study of Inhaled Nitric Oxide (iNO) and Respiratory Outcomes in Late Preterm Infants",[68,69],"2013-03",3,[1504],"Bronchopulmonary Dysplasia",[1487],{"trials":1507,"activeCount":78},[],{"trials":1509,"activeCount":78},[],{"intervention":1511,"totalTrials":110,"cells":1512},"Ambrisentan",{"EARLY_PHASE1":1513,"PHASE1":1515,"PHASE2":1517,"PHASE3":1519,"PHASE4":1531,"NA":1533},{"trials":1514,"activeCount":78},[],{"trials":1516,"activeCount":78},[],{"trials":1518,"activeCount":78},[],{"trials":1520,"activeCount":78},[1521],{"nctId":1522,"briefTitle":1523,"status":90,"phases":1524,"primaryCompletion":1525,"completion":1526,"start":1527,"enrollment":968,"conditions":1528,"interventions":1530},"NCT01224210","Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial",[69],"2016-10","2020-03","2010-03",[1529],"Portopulmonary Hypertension",[1511],{"trials":1532,"activeCount":78},[],{"trials":1534,"activeCount":78},[],{"intervention":1536,"totalTrials":74,"cells":1537},"Apremilast",{"EARLY_PHASE1":1538,"PHASE1":1540,"PHASE2":1542,"PHASE3":1561,"PHASE4":1563,"NA":1565},{"trials":1539,"activeCount":78},[],{"trials":1541,"activeCount":78},[],{"trials":1543,"activeCount":78},[1544,1554],{"nctId":1545,"briefTitle":1546,"status":90,"phases":1547,"primaryCompletion":1548,"completion":1549,"start":1550,"enrollment":340,"conditions":1551,"interventions":1553},"NCT04306965","Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab",[68],"2022-06-23","2022-08-18","2020-08-01",[1552],"Atopic Dermatitis",[1536],{"nctId":1555,"briefTitle":1556,"status":90,"phases":1557,"primaryCompletion":1527,"completion":1527,"start":197,"enrollment":340,"conditions":1558,"interventions":1560},"NCT00931242","Study of Apremilast in Atopic or Contact Dermatitis",[68],[1552,1559],"Allergic Contact Dermatitis",[1536],{"trials":1562,"activeCount":78},[],{"trials":1564,"activeCount":78},[],{"trials":1566,"activeCount":78},[],{"intervention":1568,"totalTrials":74,"cells":1569},"PZ-128",{"EARLY_PHASE1":1570,"PHASE1":1572,"PHASE2":1583,"PHASE3":1598,"PHASE4":1600,"NA":1602},{"trials":1571,"activeCount":78},[],{"trials":1573,"activeCount":78},[1574],{"nctId":1575,"briefTitle":1576,"status":90,"phases":1577,"primaryCompletion":366,"completion":366,"start":1578,"enrollment":94,"conditions":1579,"interventions":1582},"NCT01806077","Safety Study of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors",[67],"2013-04",[1580,1581],"Vascular Disease","Coronary Artery Disease Risk Factors Multiple",[1568],{"trials":1584,"activeCount":78},[1585],{"nctId":1586,"briefTitle":1587,"status":90,"phases":1588,"primaryCompletion":1589,"completion":1589,"start":1590,"enrollment":128,"conditions":1591,"interventions":1597},"NCT02561000","Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention",[68],"2019-09-17","2016-05-27",[1592,726,1180,1593,23,1594,1595,1596],"Arterial Occlusive Diseases","Arteriosclerosis","Myocardial Ischemia","Vascular Diseases","Acute Coronary Syndrome",[1568],{"trials":1599,"activeCount":78},[],{"trials":1601,"activeCount":78},[],{"trials":1603,"activeCount":78},[],{"intervention":1605,"totalTrials":110,"cells":1606},"Niclosamide",{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1623,"PHASE4":1625,"NA":1627},{"trials":1608,"activeCount":78},[],{"trials":1610,"activeCount":78},[],{"trials":1612,"activeCount":78},[1613],{"nctId":1614,"briefTitle":1615,"status":90,"phases":1616,"primaryCompletion":1617,"completion":1618,"start":1619,"enrollment":457,"conditions":1620,"interventions":1622},"NCT04399356","Niclosamide for Mild to Moderate COVID-19",[68],"2021-04-20","2021-08-19","2020-10-01",[1621],"COVID-19",[1605],{"trials":1624,"activeCount":78},[],{"trials":1626,"activeCount":78},[],{"trials":1628,"activeCount":78},[],{"intervention":1630,"totalTrials":110,"cells":1631},"Half normal saline",{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1649,"PHASE4":1651,"NA":1653},{"trials":1633,"activeCount":78},[],{"trials":1635,"activeCount":78},[],{"trials":1637,"activeCount":78},[1638],{"nctId":1639,"briefTitle":1640,"status":90,"phases":1641,"primaryCompletion":1642,"completion":1642,"start":417,"enrollment":1643,"conditions":1644,"interventions":1646},"NCT01941745","Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome",[68],"2017-08-25",88,[1645,1504],"Respiratory Distress Syndrome in Premature Infant",[1630,1647,1648],"Low Dose rhCC10","High dose rhCC10",{"trials":1650,"activeCount":78},[],{"trials":1652,"activeCount":78},[],{"trials":1654,"activeCount":78},[],{"intervention":1647,"totalTrials":110,"cells":1656},{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1661,"PHASE3":1667,"PHASE4":1669,"NA":1671},{"trials":1658,"activeCount":78},[],{"trials":1660,"activeCount":78},[],{"trials":1662,"activeCount":78},[1663],{"nctId":1639,"briefTitle":1640,"status":90,"phases":1664,"primaryCompletion":1642,"completion":1642,"start":417,"enrollment":1643,"conditions":1665,"interventions":1666},[68],[1645,1504],[1630,1647,1648],{"trials":1668,"activeCount":78},[],{"trials":1670,"activeCount":78},[],{"trials":1672,"activeCount":78},[],{"intervention":1648,"totalTrials":110,"cells":1674},{"EARLY_PHASE1":1675,"PHASE1":1677,"PHASE2":1679,"PHASE3":1685,"PHASE4":1687,"NA":1689},{"trials":1676,"activeCount":78},[],{"trials":1678,"activeCount":78},[],{"trials":1680,"activeCount":78},[1681],{"nctId":1639,"briefTitle":1640,"status":90,"phases":1682,"primaryCompletion":1642,"completion":1642,"start":417,"enrollment":1643,"conditions":1683,"interventions":1684},[68],[1645,1504],[1630,1647,1648],{"trials":1686,"activeCount":78},[],{"trials":1688,"activeCount":78},[],{"trials":1690,"activeCount":78},[],{"intervention":1692,"totalTrials":110,"cells":1693},"indium-111-ibritumomab tiuxetan",{"EARLY_PHASE1":1694,"PHASE1":1696,"PHASE2":1698,"PHASE3":1712,"PHASE4":1714,"NA":1716},{"trials":1695,"activeCount":78},[],{"trials":1697,"activeCount":78},[],{"trials":1699,"activeCount":78},[1700],{"nctId":1701,"briefTitle":1702,"status":235,"phases":1703,"primaryCompletion":1704,"completion":1705,"start":1706,"enrollment":1707,"conditions":1708,"interventions":1710},"NCT01207765","Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma",[68],"2013-01","2013-06","2008-04",8,[1709],"Multiple Myeloma",[1692,1711],"90Y Zevalin",{"trials":1713,"activeCount":78},[],{"trials":1715,"activeCount":78},[],{"trials":1717,"activeCount":78},[],{"intervention":1711,"totalTrials":110,"cells":1719},{"EARLY_PHASE1":1720,"PHASE1":1722,"PHASE2":1724,"PHASE3":1730,"PHASE4":1732,"NA":1734},{"trials":1721,"activeCount":78},[],{"trials":1723,"activeCount":78},[],{"trials":1725,"activeCount":78},[1726],{"nctId":1701,"briefTitle":1702,"status":235,"phases":1727,"primaryCompletion":1704,"completion":1705,"start":1706,"enrollment":1707,"conditions":1728,"interventions":1729},[68],[1709],[1692,1711],{"trials":1731,"activeCount":78},[],{"trials":1733,"activeCount":78},[],{"trials":1735,"activeCount":78},[],{"intervention":1737,"totalTrials":110,"cells":1738},"Eplerenone 50mg",{"EARLY_PHASE1":1739,"PHASE1":1741,"PHASE2":1743,"PHASE3":1755,"PHASE4":1757,"NA":1759},{"trials":1740,"activeCount":78},[],{"trials":1742,"activeCount":78},[],{"trials":1744,"activeCount":78},[1745],{"nctId":1746,"briefTitle":1747,"status":90,"phases":1748,"primaryCompletion":766,"completion":1749,"start":1750,"enrollment":1751,"conditions":1752,"interventions":1754},"NCT01822561","Eplerenone for Central Serous Chorioretinopathy",[68],"2017-12","2013-05",17,[1753],"Central Serous Chorioretinopathy",[1737],{"trials":1756,"activeCount":78},[],{"trials":1758,"activeCount":78},[],{"trials":1760,"activeCount":78},[],{"intervention":1762,"totalTrials":110,"cells":1763},"Fluphenazine Decanoate",{"EARLY_PHASE1":1764,"PHASE1":1766,"PHASE2":1768,"PHASE3":1779,"PHASE4":1781,"NA":1783},{"trials":1765,"activeCount":78},[],{"trials":1767,"activeCount":78},[],{"trials":1769,"activeCount":78},[1770],{"nctId":1771,"briefTitle":1772,"status":235,"phases":1773,"primaryCompletion":1774,"completion":1775,"start":1776,"enrollment":340,"conditions":1777,"interventions":1778},"NCT00356200","Fluphenazine Decanoate for Psoriasis",[68],"2007-12","2008-09","2006-07",[21],[1762],{"trials":1780,"activeCount":78},[],{"trials":1782,"activeCount":78},[],{"trials":1784,"activeCount":78},[],{"intervention":1786,"totalTrials":110,"cells":1787},"Umbilical Cord Blood After Myeloablative Conditioning",{"EARLY_PHASE1":1788,"PHASE1":1790,"PHASE2":1792,"PHASE3":1805,"PHASE4":1807,"NA":1809},{"trials":1789,"activeCount":78},[],{"trials":1791,"activeCount":78},[],{"trials":1793,"activeCount":78},[1794],{"nctId":1795,"briefTitle":1796,"status":235,"phases":1797,"primaryCompletion":723,"completion":722,"start":1798,"enrollment":16,"conditions":1799,"interventions":1803},"NCT00676806","A Phase II Study of Umbilical Cord Blood Transplantation",[68],"2005-07",[1800,1801,1709,1802],"Leukemia","Lymphoma","Aplastic Anemia",[1786,1804],"Umbilical Cord Blood After Reduced-Intensity Conditioning",{"trials":1806,"activeCount":78},[],{"trials":1808,"activeCount":78},[],{"trials":1810,"activeCount":78},[],{"intervention":1804,"totalTrials":110,"cells":1812},{"EARLY_PHASE1":1813,"PHASE1":1815,"PHASE2":1817,"PHASE3":1823,"PHASE4":1825,"NA":1827},{"trials":1814,"activeCount":78},[],{"trials":1816,"activeCount":78},[],{"trials":1818,"activeCount":78},[1819],{"nctId":1795,"briefTitle":1796,"status":235,"phases":1820,"primaryCompletion":723,"completion":722,"start":1798,"enrollment":16,"conditions":1821,"interventions":1822},[68],[1800,1801,1709,1802],[1786,1804],{"trials":1824,"activeCount":78},[],{"trials":1826,"activeCount":78},[],{"trials":1828,"activeCount":78},[],{"intervention":1830,"totalTrials":110,"cells":1831},"Crisaborole Topical Ointment",{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1836,"PHASE3":1849,"PHASE4":1851,"NA":1853},{"trials":1833,"activeCount":78},[],{"trials":1835,"activeCount":78},[],{"trials":1837,"activeCount":78},[1838],{"nctId":1839,"briefTitle":1840,"status":1841,"phases":1842,"primaryCompletion":1843,"completion":1844,"start":1845,"enrollment":78,"conditions":1846,"interventions":1848},"NCT04299503","Topical Crisaborole in Patients with Alopecia Areata","WITHDRAWN",[68],"2022-03","2022-12","2020-03-06",[1847],"Alopecia Areata",[1830],{"trials":1850,"activeCount":78},[],{"trials":1852,"activeCount":78},[],{"trials":1854,"activeCount":78},[],{"intervention":1856,"totalTrials":110,"cells":1857},"pemetrexed and gemcitabine",{"EARLY_PHASE1":1858,"PHASE1":1860,"PHASE2":1862,"PHASE3":1873,"PHASE4":1875,"NA":1877},{"trials":1859,"activeCount":78},[],{"trials":1861,"activeCount":78},[],{"trials":1863,"activeCount":78},[1864],{"nctId":1865,"briefTitle":1866,"status":235,"phases":1867,"primaryCompletion":1868,"completion":1868,"start":1869,"enrollment":110,"conditions":1870,"interventions":1872},"NCT00129974","Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer",[68],"2006-10","2005-08",[1871],"Carcinoma, Small Cell",[1856],{"trials":1874,"activeCount":78},[],{"trials":1876,"activeCount":78},[],{"trials":1878,"activeCount":78},[],{"intervention":1880,"totalTrials":110,"cells":1881},"Bendamustine Hydrochloride",{"EARLY_PHASE1":1882,"PHASE1":1884,"PHASE2":1886,"PHASE3":1899,"PHASE4":1901,"NA":1903},{"trials":1883,"activeCount":78},[],{"trials":1885,"activeCount":78},[],{"trials":1887,"activeCount":78},[1888],{"nctId":1889,"briefTitle":1890,"status":1841,"phases":1891,"primaryCompletion":1892,"completion":338,"start":1893,"enrollment":78,"conditions":1894,"interventions":1897},"NCT04943302","Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis",[68],"2024-09","2022-09-01",[1895,1896],"Amyloidosis","Light Chain (AL) Amyloidosis",[1880,1898],"Isatuximab",{"trials":1900,"activeCount":78},[],{"trials":1902,"activeCount":78},[],{"trials":1904,"activeCount":78},[],{"intervention":1898,"totalTrials":110,"cells":1906},{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1911,"PHASE3":1917,"PHASE4":1919,"NA":1921},{"trials":1908,"activeCount":78},[],{"trials":1910,"activeCount":78},[],{"trials":1912,"activeCount":78},[1913],{"nctId":1889,"briefTitle":1890,"status":1841,"phases":1914,"primaryCompletion":1892,"completion":338,"start":1893,"enrollment":78,"conditions":1915,"interventions":1916},[68],[1895,1896],[1880,1898],{"trials":1918,"activeCount":78},[],{"trials":1920,"activeCount":78},[],{"trials":1922,"activeCount":78},[],{"intervention":1053,"totalTrials":110,"cells":1924},{"EARLY_PHASE1":1925,"PHASE1":1927,"PHASE2":1929,"PHASE3":1935,"PHASE4":1937,"NA":1939},{"trials":1926,"activeCount":78},[],{"trials":1928,"activeCount":78},[],{"trials":1930,"activeCount":78},[1931],{"nctId":1044,"briefTitle":1045,"status":235,"phases":1932,"primaryCompletion":1047,"completion":1047,"start":1048,"enrollment":24,"conditions":1933,"interventions":1934},[68],[1050,1051],[1053,1054,1055,1056,424],{"trials":1936,"activeCount":78},[],{"trials":1938,"activeCount":78},[],{"trials":1940,"activeCount":78},[],{"intervention":1054,"totalTrials":110,"cells":1942},{"EARLY_PHASE1":1943,"PHASE1":1945,"PHASE2":1947,"PHASE3":1953,"PHASE4":1955,"NA":1957},{"trials":1944,"activeCount":78},[],{"trials":1946,"activeCount":78},[],{"trials":1948,"activeCount":78},[1949],{"nctId":1044,"briefTitle":1045,"status":235,"phases":1950,"primaryCompletion":1047,"completion":1047,"start":1048,"enrollment":24,"conditions":1951,"interventions":1952},[68],[1050,1051],[1053,1054,1055,1056,424],{"trials":1954,"activeCount":78},[],{"trials":1956,"activeCount":78},[],{"trials":1958,"activeCount":78},[],{"intervention":1055,"totalTrials":110,"cells":1960},{"EARLY_PHASE1":1961,"PHASE1":1963,"PHASE2":1965,"PHASE3":1971,"PHASE4":1973,"NA":1975},{"trials":1962,"activeCount":78},[],{"trials":1964,"activeCount":78},[],{"trials":1966,"activeCount":78},[1967],{"nctId":1044,"briefTitle":1045,"status":235,"phases":1968,"primaryCompletion":1047,"completion":1047,"start":1048,"enrollment":24,"conditions":1969,"interventions":1970},[68],[1050,1051],[1053,1054,1055,1056,424],{"trials":1972,"activeCount":78},[],{"trials":1974,"activeCount":78},[],{"trials":1976,"activeCount":78},[],{"intervention":1056,"totalTrials":110,"cells":1978},{"EARLY_PHASE1":1979,"PHASE1":1981,"PHASE2":1983,"PHASE3":1989,"PHASE4":1991,"NA":1993},{"trials":1980,"activeCount":78},[],{"trials":1982,"activeCount":78},[],{"trials":1984,"activeCount":78},[1985],{"nctId":1044,"briefTitle":1045,"status":235,"phases":1986,"primaryCompletion":1047,"completion":1047,"start":1048,"enrollment":24,"conditions":1987,"interventions":1988},[68],[1050,1051],[1053,1054,1055,1056,424],{"trials":1990,"activeCount":78},[],{"trials":1992,"activeCount":78},[],{"trials":1994,"activeCount":78},[],{"intervention":1996,"totalTrials":110,"cells":1997},"Vitamin D3 2,000 IU orally once daily",{"EARLY_PHASE1":1998,"PHASE1":2000,"PHASE2":2002,"PHASE3":2018,"PHASE4":2020,"NA":2022},{"trials":1999,"activeCount":78},[],{"trials":2001,"activeCount":78},[],{"trials":2003,"activeCount":78},[2004],{"nctId":2005,"briefTitle":2006,"status":90,"phases":2007,"primaryCompletion":237,"completion":237,"start":2008,"enrollment":2009,"conditions":2010,"interventions":2014},"NCT00436475","Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes",[67,68],"2007-09",92,[2011,2012,2013],"Glucose Intolerance","Type 2 Diabetes Mellitus","Metabolic Syndrome",[1996,2015,2016,2017],"Calcium Carbonate 400 mg orally twice daily","Vitamin D3-Placebo","Calcium-Placebo",{"trials":2019,"activeCount":78},[],{"trials":2021,"activeCount":78},[],{"trials":2023,"activeCount":78},[],{"intervention":2015,"totalTrials":110,"cells":2025},{"EARLY_PHASE1":2026,"PHASE1":2028,"PHASE2":2030,"PHASE3":2036,"PHASE4":2038,"NA":2040},{"trials":2027,"activeCount":78},[],{"trials":2029,"activeCount":78},[],{"trials":2031,"activeCount":78},[2032],{"nctId":2005,"briefTitle":2006,"status":90,"phases":2033,"primaryCompletion":237,"completion":237,"start":2008,"enrollment":2009,"conditions":2034,"interventions":2035},[67,68],[2011,2012,2013],[1996,2015,2016,2017],{"trials":2037,"activeCount":78},[],{"trials":2039,"activeCount":78},[],{"trials":2041,"activeCount":78},[],{"intervention":2016,"totalTrials":110,"cells":2043},{"EARLY_PHASE1":2044,"PHASE1":2046,"PHASE2":2048,"PHASE3":2054,"PHASE4":2056,"NA":2058},{"trials":2045,"activeCount":78},[],{"trials":2047,"activeCount":78},[],{"trials":2049,"activeCount":78},[2050],{"nctId":2005,"briefTitle":2006,"status":90,"phases":2051,"primaryCompletion":237,"completion":237,"start":2008,"enrollment":2009,"conditions":2052,"interventions":2053},[67,68],[2011,2012,2013],[1996,2015,2016,2017],{"trials":2055,"activeCount":78},[],{"trials":2057,"activeCount":78},[],{"trials":2059,"activeCount":78},[],{"intervention":2017,"totalTrials":110,"cells":2061},{"EARLY_PHASE1":2062,"PHASE1":2064,"PHASE2":2066,"PHASE3":2072,"PHASE4":2074,"NA":2076},{"trials":2063,"activeCount":78},[],{"trials":2065,"activeCount":78},[],{"trials":2067,"activeCount":78},[2068],{"nctId":2005,"briefTitle":2006,"status":90,"phases":2069,"primaryCompletion":237,"completion":237,"start":2008,"enrollment":2009,"conditions":2070,"interventions":2071},[67,68],[2011,2012,2013],[1996,2015,2016,2017],{"trials":2073,"activeCount":78},[],{"trials":2075,"activeCount":78},[],{"trials":2077,"activeCount":78},[],{"intervention":2079,"totalTrials":110,"cells":2080},"Infliximab",{"EARLY_PHASE1":2081,"PHASE1":2083,"PHASE2":2085,"PHASE3":2095,"PHASE4":2097,"NA":2099},{"trials":2082,"activeCount":78},[],{"trials":2084,"activeCount":78},[],{"trials":2086,"activeCount":78},[2087],{"nctId":2088,"briefTitle":2089,"status":90,"phases":2090,"primaryCompletion":2091,"completion":2091,"start":2092,"enrollment":1751,"conditions":2093,"interventions":2094},"NCT04425538","A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).",[68],"2021-01-22","2020-06-01",[1621],[2079],{"trials":2096,"activeCount":78},[],{"trials":2098,"activeCount":78},[],{"trials":2100,"activeCount":78},[],{"intervention":2102,"totalTrials":110,"cells":2103},"Cyclophosphamide and docetaxel",{"EARLY_PHASE1":2104,"PHASE1":2106,"PHASE2":2108,"PHASE3":2117,"PHASE4":2119,"NA":2121},{"trials":2105,"activeCount":78},[],{"trials":2107,"activeCount":78},[],{"trials":2109,"activeCount":78},[2110],{"nctId":2111,"briefTitle":2112,"status":1841,"phases":2113,"primaryCompletion":195,"completion":195,"start":2114,"enrollment":78,"conditions":2115,"interventions":2116},"NCT01229605","Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer",[68],"2010-10",[28],[2102],{"trials":2118,"activeCount":78},[],{"trials":2120,"activeCount":78},[],{"trials":2122,"activeCount":78},[],{"intervention":1085,"totalTrials":110,"cells":2124},{"EARLY_PHASE1":2125,"PHASE1":2127,"PHASE2":2129,"PHASE3":2135,"PHASE4":2137,"NA":2139},{"trials":2126,"activeCount":78},[],{"trials":2128,"activeCount":78},[],{"trials":2130,"activeCount":78},[2131],{"nctId":1077,"briefTitle":1078,"status":90,"phases":2132,"primaryCompletion":1080,"completion":1080,"start":1081,"enrollment":1082,"conditions":2133,"interventions":2134},[68],[28],[1068,1085],{"trials":2136,"activeCount":78},[],{"trials":2138,"activeCount":78},[],{"trials":2140,"activeCount":78},[],{"intervention":2142,"totalTrials":110,"cells":2143},"Dexmedetomidine",{"EARLY_PHASE1":2144,"PHASE1":2146,"PHASE2":2148,"PHASE3":2158,"PHASE4":2160,"NA":2162},{"trials":2145,"activeCount":78},[],{"trials":2147,"activeCount":78},[],{"trials":2149,"activeCount":78},[2150],{"nctId":2151,"briefTitle":2152,"status":90,"phases":2153,"primaryCompletion":2154,"completion":2154,"start":239,"enrollment":839,"conditions":2155,"interventions":2157},"NCT00871624","Efficacy and Safety of Dexmedetomidine During Non-Invasive Positive Pressure Ventilation",[68],"2013-02",[2156],"Acute Respiratory Failure",[2142],{"trials":2159,"activeCount":78},[],{"trials":2161,"activeCount":78},[],{"trials":2163,"activeCount":78},[],{"intervention":2165,"totalTrials":110,"cells":2166},"Ruxolitinib 1.5% Phosphate Cream",{"EARLY_PHASE1":2167,"PHASE1":2169,"PHASE2":2171,"PHASE3":2183,"PHASE4":2185,"NA":2187},{"trials":2168,"activeCount":78},[],{"trials":2170,"activeCount":78},[],{"trials":2172,"activeCount":78},[2173],{"nctId":2174,"briefTitle":2175,"status":90,"phases":2176,"primaryCompletion":2177,"completion":2178,"start":2179,"enrollment":11,"conditions":2180,"interventions":2182},"NCT02809976","Topical Ruxolitinib for the Treatment of Vitiligo",[68],"2017-01","2017-02","2016-01",[2181],"Vitiligo",[2165],{"trials":2184,"activeCount":78},[],{"trials":2186,"activeCount":78},[],{"trials":2188,"activeCount":78},[],{"intervention":2190,"totalTrials":110,"cells":2191},"Fluphenazine",{"EARLY_PHASE1":2192,"PHASE1":2194,"PHASE2":2196,"PHASE3":2207,"PHASE4":2209,"NA":2211},{"trials":2193,"activeCount":78},[],{"trials":2195,"activeCount":78},[],{"trials":2197,"activeCount":78},[2198],{"nctId":2199,"briefTitle":2200,"status":90,"phases":2201,"primaryCompletion":2202,"completion":2203,"start":2204,"enrollment":9,"conditions":2205,"interventions":2206},"NCT00929578","Fluphenazine Hydrochloride for Psoriasis",[68],"2010-11","2011-01","2008-11",[21],[2190],{"trials":2208,"activeCount":78},[],{"trials":2210,"activeCount":78},[],{"trials":2212,"activeCount":78},[],{"intervention":2214,"totalTrials":110,"cells":2215},"sodium oxybate",{"EARLY_PHASE1":2216,"PHASE1":2218,"PHASE2":2220,"PHASE3":2231,"PHASE4":2233,"NA":2235},{"trials":2217,"activeCount":78},[],{"trials":2219,"activeCount":78},[],{"trials":2221,"activeCount":78},[2222],{"nctId":2223,"briefTitle":2224,"status":1841,"phases":2225,"primaryCompletion":2226,"completion":2226,"start":2227,"enrollment":78,"conditions":2228,"interventions":2230},"NCT00744393","The Effect of Sodium Oxybate on Sleep Architecture",[68],"2009-12","2008-10",[2229],"Mechanically Ventilated ICU Patients",[2214],{"trials":2232,"activeCount":78},[],{"trials":2234,"activeCount":78},[],{"trials":2236,"activeCount":78},[],{"intervention":2238,"totalTrials":110,"cells":2239},"NEOD001",{"EARLY_PHASE1":2240,"PHASE1":2242,"PHASE2":2244,"PHASE3":2255,"PHASE4":2257,"NA":2259},{"trials":2241,"activeCount":78},[],{"trials":2243,"activeCount":78},[],{"trials":2245,"activeCount":78},[2246],{"nctId":2247,"briefTitle":2248,"status":235,"phases":2249,"primaryCompletion":2250,"completion":2251,"start":2252,"enrollment":497,"conditions":2253,"interventions":2254},"NCT03168906","Renal AL Amyloid Involvement and NEOD001",[68],"2018-04-23","2019-02-06","2017-07-05",[1895],[2238],{"trials":2256,"activeCount":78},[],{"trials":2258,"activeCount":78},[],{"trials":2260,"activeCount":78},[],{"intervention":2262,"totalTrials":110,"cells":2263},"Nitric Oxide",{"EARLY_PHASE1":2264,"PHASE1":2266,"PHASE2":2268,"PHASE3":2278,"PHASE4":2280,"NA":2282},{"trials":2265,"activeCount":78},[],{"trials":2267,"activeCount":78},[],{"trials":2269,"activeCount":78},[2270],{"nctId":2271,"briefTitle":2272,"status":235,"phases":2273,"primaryCompletion":2274,"completion":2274,"start":2275,"enrollment":340,"conditions":2276,"interventions":2277},"NCT04388683","Inhaled Nitric Oxide for Preventing Progression in COVID-19",[68],"2020-11-23","2020-05-12",[1621],[2262],{"trials":2279,"activeCount":78},[],{"trials":2281,"activeCount":78},[],{"trials":2283,"activeCount":78},[],{"intervention":2285,"totalTrials":110,"cells":2286},"Lactobacillus GG or Culturelle",{"EARLY_PHASE1":2287,"PHASE1":2289,"PHASE2":2300,"PHASE3":2302,"PHASE4":2304,"NA":2306},{"trials":2288,"activeCount":78},[],{"trials":2290,"activeCount":78},[2291],{"nctId":2292,"briefTitle":2293,"status":235,"phases":2294,"primaryCompletion":2295,"completion":2295,"start":2296,"enrollment":11,"conditions":2297,"interventions":2299},"NCT00756262","Probiotic Lactobacillus GG to Eliminate VRE Colonization",[67],"2012-07","2003-03",[2298],"Vancomycin Resistant Enterococcal Colonization",[2285],{"trials":2301,"activeCount":78},[],{"trials":2303,"activeCount":78},[],{"trials":2305,"activeCount":78},[],{"trials":2307,"activeCount":78},[],{"intervention":2309,"totalTrials":110,"cells":2310},"Venetoclax",{"EARLY_PHASE1":2311,"PHASE1":2313,"PHASE2":2325,"PHASE3":2327,"PHASE4":2329,"NA":2331},{"trials":2312,"activeCount":78},[],{"trials":2314,"activeCount":78},[2315],{"nctId":2316,"briefTitle":2317,"status":235,"phases":2318,"primaryCompletion":2319,"completion":2320,"start":2177,"enrollment":1502,"conditions":2321,"interventions":2323},"NCT03000660","Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis",[67],"2019-10","2019-10-10",[2322],"AL Amyloidosis",[2309,2324],"Dexamethasone",{"trials":2326,"activeCount":78},[],{"trials":2328,"activeCount":78},[],{"trials":2330,"activeCount":78},[],{"trials":2332,"activeCount":78},[],{"intervention":2324,"totalTrials":110,"cells":2334},{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2343,"PHASE3":2345,"PHASE4":2347,"NA":2349},{"trials":2336,"activeCount":78},[],{"trials":2338,"activeCount":78},[2339],{"nctId":2316,"briefTitle":2317,"status":235,"phases":2340,"primaryCompletion":2319,"completion":2320,"start":2177,"enrollment":1502,"conditions":2341,"interventions":2342},[67],[2322],[2309,2324],{"trials":2344,"activeCount":78},[],{"trials":2346,"activeCount":78},[],{"trials":2348,"activeCount":78},[],{"trials":2350,"activeCount":78},[],{"intervention":2352,"totalTrials":110,"cells":2353},"Cenegermin-Bkbj",{"EARLY_PHASE1":2354,"PHASE1":2356,"PHASE2":2368,"PHASE3":2370,"PHASE4":2372,"NA":2374},{"trials":2355,"activeCount":78},[],{"trials":2357,"activeCount":78},[2358],{"nctId":2359,"briefTitle":2360,"status":1841,"phases":2361,"primaryCompletion":2362,"completion":2362,"start":2363,"enrollment":78,"conditions":2364,"interventions":2367},"NCT05700864","NGF Treatment for Patients With Neuropathic Corneal Pain",[67],"2023-12-01","2022-11-01",[2365,2366],"Corneal Disease","Neuropathy",[2352],{"trials":2369,"activeCount":78},[],{"trials":2371,"activeCount":78},[],{"trials":2373,"activeCount":78},[],{"trials":2375,"activeCount":78},[],{"intervention":2377,"totalTrials":110,"cells":2378},"Docetaxel",{"EARLY_PHASE1":2379,"PHASE1":2381,"PHASE2":2393,"PHASE3":2395,"PHASE4":2397,"NA":2399},{"trials":2380,"activeCount":78},[],{"trials":2382,"activeCount":78},[2383],{"nctId":2384,"briefTitle":2385,"status":90,"phases":2386,"primaryCompletion":811,"completion":2387,"start":2388,"enrollment":2389,"conditions":2390,"interventions":2392},"NCT03737370","Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer",[67],"2025-09-30","2018-01-30",43,[2391],"Metastatic Castrate Resistant Prostate Cancer",[2377],{"trials":2394,"activeCount":78},[],{"trials":2396,"activeCount":78},[],{"trials":2398,"activeCount":78},[],{"trials":2400,"activeCount":78},[],{"intervention":2402,"totalTrials":110,"cells":2403},"NK-Cell",{"EARLY_PHASE1":2404,"PHASE1":2406,"PHASE2":2418,"PHASE3":2420,"PHASE4":2422,"NA":2424},{"trials":2405,"activeCount":78},[],{"trials":2407,"activeCount":78},[2408],{"nctId":2409,"briefTitle":2410,"status":90,"phases":2411,"primaryCompletion":2412,"completion":2412,"start":2413,"enrollment":2414,"conditions":2415,"interventions":2417},"NCT00660166","Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions",[67],"2012-06","2006-04",13,[1801,2416,1800],"Myeloma",[2402],{"trials":2419,"activeCount":78},[],{"trials":2421,"activeCount":78},[],{"trials":2423,"activeCount":78},[],{"trials":2425,"activeCount":78},[],{"intervention":2427,"totalTrials":110,"cells":2428},"Influenza Virus Vaccine Live, Intranasal",{"EARLY_PHASE1":2429,"PHASE1":2431,"PHASE2":2442,"PHASE3":2444,"PHASE4":2446,"NA":2448},{"trials":2430,"activeCount":78},[],{"trials":2432,"activeCount":78},[2433],{"nctId":2434,"briefTitle":2435,"status":90,"phases":2436,"primaryCompletion":2437,"completion":2226,"start":2008,"enrollment":2438,"conditions":2439,"interventions":2441},"NCT00620412","Probiotics to Enhance Immunogenicity of Influenza Vaccine in Healthy Adults",[67],"2008-06",52,[2440],"Healthy",[2427],{"trials":2443,"activeCount":78},[],{"trials":2445,"activeCount":78},[],{"trials":2447,"activeCount":78},[],{"trials":2449,"activeCount":78},[],{"intervention":2451,"totalTrials":110,"cells":2452},"Aflibercept",{"EARLY_PHASE1":2453,"PHASE1":2455,"PHASE2":2467,"PHASE3":2469,"PHASE4":2471,"NA":2473},{"trials":2454,"activeCount":78},[],{"trials":2456,"activeCount":78},[2457],{"nctId":2458,"briefTitle":2459,"status":235,"phases":2460,"primaryCompletion":2461,"completion":2462,"start":2463,"enrollment":110,"conditions":2464,"interventions":2466},"NCT03396861","Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept",[67],"2019-08-18","2020-01-02","2019-02-22",[2465],"Irvine-Gass Syndrome",[2451],{"trials":2468,"activeCount":78},[],{"trials":2470,"activeCount":78},[],{"trials":2472,"activeCount":78},[],{"trials":2474,"activeCount":78},[],{"intervention":2476,"totalTrials":110,"cells":2477},"Trichuris Suis Ova",{"EARLY_PHASE1":2478,"PHASE1":2480,"PHASE2":2489,"PHASE3":2491,"PHASE4":2493,"NA":2495},{"trials":2479,"activeCount":78},[],{"trials":2481,"activeCount":78},[2482],{"nctId":2483,"briefTitle":2484,"status":235,"phases":2485,"primaryCompletion":2486,"completion":2486,"start":723,"enrollment":1502,"conditions":2487,"interventions":2488},"NCT01948271","Efficacy Study of Trichuris Suis Ova to Treat Chronic Plaque Psoriasis",[67],"2014-09",[21],[2476],{"trials":2490,"activeCount":78},[],{"trials":2492,"activeCount":78},[],{"trials":2494,"activeCount":78},[],{"trials":2496,"activeCount":78},[],{"intervention":2498,"totalTrials":110,"cells":2499},"Plerixafor",{"EARLY_PHASE1":2500,"PHASE1":2502,"PHASE2":2513,"PHASE3":2515,"PHASE4":2517,"NA":2519},{"trials":2501,"activeCount":78},[],{"trials":2503,"activeCount":78},[2504],{"nctId":2505,"briefTitle":2506,"status":235,"phases":2507,"primaryCompletion":2508,"completion":2509,"start":723,"enrollment":16,"conditions":2510,"interventions":2512},"NCT01610999","Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation",[67],"2014-06","2015-12",[2511,1801,1709],"Chronic Lymphocytic Leukemia",[2498],{"trials":2514,"activeCount":78},[],{"trials":2516,"activeCount":78},[],{"trials":2518,"activeCount":78},[],{"trials":2520,"activeCount":78},[],{"intervention":2522,"totalTrials":110,"cells":2523},"Gabapentin 300 mg PO at 8 PM",{"EARLY_PHASE1":2524,"PHASE1":2537,"PHASE2":2539,"PHASE3":2541,"PHASE4":2543,"NA":2545},{"trials":2525,"activeCount":78},[2526],{"nctId":2527,"briefTitle":2528,"status":90,"phases":2529,"primaryCompletion":2530,"completion":2531,"start":2532,"enrollment":2533,"conditions":2534,"interventions":2536},"NCT04631510","Gabapentin for Sleep in Critically Ill Patients",[66],"2023-08-04","2025-05-30","2020-12-01",80,[2535],"Intensive Care Unit Sleep Disruption",[2522],{"trials":2538,"activeCount":78},[],{"trials":2540,"activeCount":78},[],{"trials":2542,"activeCount":78},[],{"trials":2544,"activeCount":78},[],{"trials":2546,"activeCount":78},[],{"intervention":2548,"totalTrials":110,"cells":2549},"Tofacitinib citrate",{"EARLY_PHASE1":2550,"PHASE1":2563,"PHASE2":2565,"PHASE3":2567,"PHASE4":2569,"NA":2571},{"trials":2551,"activeCount":78},[2552],{"nctId":2553,"briefTitle":2554,"status":235,"phases":2555,"primaryCompletion":2556,"completion":2557,"start":2558,"enrollment":24,"conditions":2559,"interventions":2562},"NCT03159936","Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)",[66],"2020-05-13","2020-06-10","2017-04-03",[2560,2561],"Discoid Lupus Erythematosus","Systemic Lupus Erythematosus",[2548],{"trials":2564,"activeCount":78},[],{"trials":2566,"activeCount":78},[],{"trials":2568,"activeCount":78},[],{"trials":2570,"activeCount":78},[],{"trials":2572,"activeCount":78},[],{"intervention":2574,"totalTrials":110,"cells":2575},"secukinumab",{"EARLY_PHASE1":2576,"PHASE1":2588,"PHASE2":2590,"PHASE3":2592,"PHASE4":2594,"NA":2596},{"trials":2577,"activeCount":78},[2578],{"nctId":2579,"briefTitle":2580,"status":90,"phases":2581,"primaryCompletion":2582,"completion":2583,"start":2584,"enrollment":383,"conditions":2585,"interventions":2587},"NCT03099980","Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa",[66],"2018-12","2019-01","2016-07-11",[2586],"Hidradenitis Suppurativa",[2574],{"trials":2589,"activeCount":78},[],{"trials":2591,"activeCount":78},[],{"trials":2593,"activeCount":78},[],{"trials":2595,"activeCount":78},[],{"trials":2597,"activeCount":78},[],{"intervention":2599,"totalTrials":110,"cells":2600},"Inulin",{"EARLY_PHASE1":2601,"PHASE1":2603,"PHASE2":2605,"PHASE3":2607,"PHASE4":2609,"NA":2611},{"trials":2602,"activeCount":78},[],{"trials":2604,"activeCount":78},[],{"trials":2606,"activeCount":78},[],{"trials":2608,"activeCount":78},[],{"trials":2610,"activeCount":78},[],{"trials":2612,"activeCount":78},[2613],{"nctId":2614,"briefTitle":2615,"status":1841,"phases":2616,"primaryCompletion":2617,"completion":367,"start":2618,"enrollment":78,"conditions":2619,"interventions":2620},"NCT00938561","Evaluation of New Markers to Assess Kidney Function",[],"2010-09","2009-09",[26],[2599],{"intervention":2622,"totalTrials":110,"cells":2623},"Ustekinumab",{"EARLY_PHASE1":2624,"PHASE1":2626,"PHASE2":2628,"PHASE3":2630,"PHASE4":2632,"NA":2634},{"trials":2625,"activeCount":78},[],{"trials":2627,"activeCount":78},[],{"trials":2629,"activeCount":78},[],{"trials":2631,"activeCount":78},[],{"trials":2633,"activeCount":78},[],{"trials":2635,"activeCount":78},[2636],{"nctId":2637,"briefTitle":2638,"status":90,"phases":2639,"primaryCompletion":2640,"completion":966,"start":471,"enrollment":2641,"conditions":2642,"interventions":2644},"NCT01090063","Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis",[71],"2012-02",26,[2643],"Moderate to Severe Palmar Plantar Psoriasis",[2622]]